

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

UGUPAJABI: Abiraterone with Prednisone for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer

HNOTDCABO: Cabozantinib for Advanced Differentiated Thyroid Cancer

LYCLLZANU: Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Cancer Drug Manual[®]

New: Pertuzumab-trastuzumab **Revised:** Chlormethine, Elranatamab, Epcoritamab, Fludarabine; Editorial Board Changes

Benefit Drug List,

New: UGUPAJABI, HNOTDCABO, LYCLLZANU, Pediatric **Revised:** ULYZANU (ULYWZANU)

NEW Protocols, PPPOs and Patient Handouts

GU UGUPAJABI **HN** HNOTDCABO **LY** LYCLLZANU, LYFZANU **SC** SCICANS

REVISED Protocols, PPPOs and Patient Handouts

BR UBRAJABEAI, UBRAJABET, BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJACTW, BRAJPNCT, BRAJTTW, BRAVA7, BRAVABR, BRAVABR, BRAVGEMT, BRAVPP, BRAVPRAT, BRAVSG, BRAVTAX, BRAVTW, BRLACPNAC, BRLACPNACG, BRLACTWAC, BRLACTWACG, BRLAPNAC, BRLAPNACG, BRLATACG, BRLATWAC, BRPCTAC, BRPCWTAC | **CN** CNAJ12TZRT, CNAJTZRT, CNELTZRT | **GI** GIPGEMABR | **GO** GOCABR, GOCABRBEV, GOCXCPNBP, GOCXCPNP, GOSADG | **GU** GUBDDMVAC | **HN** HNOTLEN | **LU** LUAVPEM, LUAVPMTN | **LK** LKATOATRA, LKATOP, LKATOR | **LY** LYACAL, LYFACAL, LYFIBRU, LYIBRU, LYIDELAR, LYOBCHLOR, LYVENOB, ULYWMZANU | **MY** MYBLDF, MYBLDPRE, MYBORMTN, MYBORPRE, MYBORREL, MYBSD, MYCARDEX, MYCARLD, MYDARBD, MYDARCBD, MYDARLD, MYDARLDF, MYLDREL, UMYISACARD, UMYISAPOMD, UMYLDF, MYLENMTN, MYMP, MYMPBOR, UMYPOMDEX | **SA** SAAVGEMD

Resources and Contact Information

Editor's Choice

New Programs

Effective 01 March 2024, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

Genitourinary

Abiraterone with Prednisone for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer (UGUPAJABI) — The BC Cancer Genitourinary Tumour Group is introducing abiraterone with prednisone for patients with non-metastatic prostate cancer but very high risk of recurrence. In a meta-analysis of primary two phase III trials (STAMPEDE), the addition of abiraterone with prednisone to androgen-deprivation therapy was associated with improved metastasis-free survival (hazard ratio [HR] 0.53), overall survival (HR 0.60), and progression-free survival (HR 0.44). Abiraterone with prednisone was associated with manageable toxicities consistent with known safety profile.[1]

Editor's Choice

New Programs

Head and Neck

Cabozantinib for Advanced Differentiated Thyroid Cancer (HNOTDCABO) — The BC Cancer Head and Neck Tumour Group is introducing cabozantinib for adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) after failing vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are refractory or ineligible to radioactive iodine. There are currently no funded therapy options for this patient population. In a phase III COSMIC-311 trial comparing to placebo, cabozantinib was associated with improved progression-free survival (11.1 vs 1.9 mos, hazard ratio 0.22) and overall response rate (15% vs. 0%). Cabozantinib was associated with manageable toxicities consistent with known safety profile.[2]

Lymphoma

Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (LYCLLZANU) — The BC Cancer Lymphoma Tumour Group is introducing zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in the previously untreated and relapsed/refractory setting. In the phase III SEQUOIA trial compared to bendamustine-rituximab, zanubrutinib was associated with improved progression-free survival in patients with treatment-naïve CLL/SLL (median not reached vs. 33.7 mos, hazard ratio 0.42). In the phase III ALPINE trial compared to ibrutinib, zanubrutinib was associated with improved overall response rate (78.3% vs. 62.5%) in patients with relapsed or refractory CLL/SLL. Zanubrutinib was associated with manageable toxicities consistent with known safety profile.[3]

References

1. Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. *Lancet* 2022;399(10323):447-60.
2. Cabozantinib (CABOMETYX) CADTH Reimbursement Recommendation. *Canadian Journal of Health Technologies* 2022;2(11):1-14.
3. Zanubrutinib (BRUKINSA) CADTH Reimbursement Recommendation. *Canadian Journal of Health Technologies* 2023;3(19):1-27.

Cancer Drug Manual[®]

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monographs and Chemotherapy Preparation and Stability Chart entry is made available for reference only.

The **Pertuzumab-trastuzumab Interim Monograph** has been developed. Pertuzumab-trastuzumab is a combination product containing pertuzumab and trastuzumab in a single injection for subcutaneous administration. Pertuzumab-trastuzumab is used in the treatment of breast cancer. Pertuzumab-trastuzumab is given as a loading dose of 1200 mg-600 mg (15 mL) on day 1 of the first cycle, followed by maintenance doses of 600 mg-600 mg (10 mL) given every three weeks thereafter.

Cancer Drug Manual[®]

Highlights from this document includes:

- injection-related reactions are likely related to the release of cytokines that occurs within 24 hours of the injection and include fever, chills, and headache
- doses are to be administered as a single injection into the thigh
- dose reductions are not recommended
- treatment interruptions of 6 weeks or longer require a repeat loading dose

Pertuzumab-trastuzumab has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Chlormethine Interim Patient Handout

Safe handling bullet for Caregiver: added “nitrile” as an example of a suitable disposable glove type

Elranatamab Interim Monograph and Chemotherapy Preparation and Stability Chart

Supply and Storage: added marketed supply; deleted information pertaining only to Special Access Program (SAP) supply

Solution Preparation and Compatibility: deleted information pertaining only to SAP supply

Chemotherapy Preparation and Stability Chart: added marketed supply; delete SAP supply

Eporitamab Interim Monograph and Chemotherapy Preparation and Stability Chart

Chemotherapy Preparation and Stability Chart: added marketed supply, which does not prohibit the use of closed system transfer device

Fludarabine Monograph

Uses: updated indications for use per current sources

Special Precautions: updated *Contraindications*

Cautions: deleted standalone paragraph for Hepatitis B reactivation; added new link for SCHBV protocol; added new bullet regarding renal elimination

Carcinogenicity: added relevant human data

Fertility: added relevant animal data

Pregnancy: deleted FDA Pregnancy category and added relevant human and animal data

Breastfeeding: added relevant animal data

Side Effects: updated reference for Extravasation Hazard per current Systemic Therapy Policy III-20; updated emetogenic potential per current SCNAUSEA protocol

Supply and Storage: updated brand information with current marketed Canadian products

Solution Preparation and Compatibility: updated per current template style

Editorial Board Changes

The Cancer Drug Manual[®] Editorial Review Board would like to welcome back Khushminder Rai as she resumes her role as CON Pharmacy Educator for BC Cancer – Surrey. Thank you **Alysha Bharmal**, Clinical Pharmacist, BC Cancer – Surrey for serving on the Editorial Board during Khushminder’s absence. Alysha will return to her previous role on the Cancer Drug Manual writing team as Cancer Drug Manual writer.

Benefit Drug List

New Programs

Effective 01 March 2024, the following new treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and predniSONE	UGUPAJABI	Restricted
Therapy of Advanced Differentiated Thyroid Cancer using Cabozantinib	HNOTDCABO	Class I
Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Zanubrutinib	LYCLLZANU	Class I
Bortezomib with chemotherapy for pediatric patients with T-cell lymphoblastic lymphoma treated with on the AALL1231 study	Pediatric	Class I
Dexrazoxane for pediatric patients with anticipated cumulative anthracycline dose >150 mg/m ² or with past or anticipated radiotherapy including the pericardium (including whole-abdomen or left flank irradiation)	Pediatric	Class I

Revised Programs

Effective 01 March 2024, the following new treatment program has been revised on the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Zanubrutinib	ULYWMZANU (previously ULYZANU)	Restricted

Community Oncology Network (CON)

2023-2024 OSCAR Billing Deadline: 04 April 2024

The 2023-2024 fiscal year will end on Sunday 31 March 2024. To meet the deadline for external reporting to the Ministry of Health, all claims for drug reimbursement for the current fiscal year must be submitted by **Thursday 04 April 2024** via **OSCAR (Online System for Cancer Drugs Adjudication and Reimbursement)**. Any claims submitted after this date will not be eligible for reimbursement. For more information, please e-mail oscar@bccancer.bc.ca.

List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Code	Protocol Title	Protocol	PPPO	Handout
UGUPAJABI	Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and predniSONE	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
HNOTDCABO	Therapy of Advanced Differentiated Thyroid Cancer using Cabozantinib	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
LYCLLZANU	Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Zanubrutinib	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
SCICANS	Management of Immune Effector Cell-Associated Neurotoxicity Syndrome	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
UBRAJABEAI	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	<i>Tests clarified</i>	<i>Tests clarified</i>	--
UBRAJABET	Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	<i>Tests clarified</i>	<i>Tests clarified</i>	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
BRAJACT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Hypersensitivity</i>	--	--
BRAJACTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide followed by PACLitaxel	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Hypersensitivity</i>	--	--
BRAJACTT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Hypersensitivity</i>	--	--
BRAJACTTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Hypersensitivity</i>	--	--
BRAJACTW	Neoadjuvant or Adjuvant Therapy for Early Breast Cancer Using DOXOrubicin and Cyclophosphamide followed by Weekly PACLitaxel	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--
BRAJPNCT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab	<i>Premedications and precautions clarified</i>	--	--
BRAJTTW	Adjuvant Therapy for Breast Cancer using Weekly PACLitaxel and Trastuzumab	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
BRAVA7	Palliative Therapy for Metastatic Breast Cancer using Weekly DOXOrubicin	<i>Eligibility and exclusion clarified</i>	--	--
BRAVABR	Palliative Therapy for Metastatic Breast Cancer using PACLitaxel NAB (ABRAXANE)	<i>Precautions clarified</i>	<i>Hypersensitivity tray and protocol reminder removed</i>	--
BRAVGEMT	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine and PACLitaxel	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Hypersensitivity</i>	--	--
BRAVPP	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with PACLitaxel	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--
BRAVPTRAT	Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and PACLitaxel as First-Line Treatment for Advanced Breast Cancer	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Hypersensitivity</i>	--	--
BRAVSG	Palliative Therapy for Metastatic Triple Negative Breast Cancer using Sacituzumab Govitecan	<i>Premedications updated</i>	--	--
BRAVTAX	Palliative Therapy for Metastatic Breast Cancer using PACLitaxel	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Hypersensitivity</i>	--	--
BRAVTW	Palliative Therapy for Metastatic Breast Cancer using Weekly PACLitaxel (3 Weeks out of 4 Weeks Schedule)	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol Title	Protocol	PPPO	Handout
BRLACPNA	Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	<i>Premedications and precautions clarified</i>	--	--
BRLACPNA	Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	<i>Premedications and precautions clarified</i>	--	--
BRLACTWA	NEOAdjuvant Therapy for Triple Negative Breast Cancer Using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--
BRLACTWA	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--
BRLAPNA	Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	<i>Precautions clarified</i>	--	--
BRLAPNA	Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	<i>Precautions clarified</i>	--	--
BRLATA	NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel followed by DOXOrubicin and Cyclophosphamide	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Hypersensitivity</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
BRLATWAC	NEOAdjuvant Therapy for Locally Advanced Breast Cancer using Weekly PACLitaxel followed by DOXOrubicin and Cyclophosphamide	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--
BRPCTAC	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--
BRPCWTAC	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	<i>Premedication and precautions updated. Deleted 25 mg dose for IV diphenhydrAMINE under Infusion related reactions</i>	--	--
CN Neuro-Oncology				
CNAJ12TZRT	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation	--	<i>Treatment scheduling with radiotherapy clarified</i>	--
CNAJTZRT	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	--	<i>Treatment scheduling with radiotherapy clarified</i>	--
CNELTZRT	Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy	--	<i>Treatment scheduling with radiotherapy clarified</i>	--
GI Gastrointestinal				
GIPGEMABR	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel NAB (ABRAXANE) and Gemcitabine	<i>Exclusions, premedications, SCNAUSEA hyperlink and precautions updated</i>	<i>Hypersensitivity tray and protocol reminder removed</i>	--
GO Gynecologic				
GOCABR	Alternative Treatment of Gynecological Malignancies using CARBOplatin and PACLitaxel NAB (ABRAXANE)	<i>Premedications and precautions clarified</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GOCABRBEV	Alternative Treatment of Gynecological Malignancies using Bevacizumab, CARBOplatin and PACLitaxel NAB (ABRAXANE)	<i>Premedications and precautions clarified</i>	--	--
GOCXCPNBP	Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and Pembrolizumab	<i>Premedications and precautions clarified</i>	--	--
GOCXCPNP	Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel NAB (ABRAXANE), and Pembrolizumab	<i>Premedications and precautions clarified</i>	--	--
GOSADG	Treatment of Uterine Sarcoma Cancer Using DOCEtaxel and Gemcitabine	<i>Treatment duration updated</i>	--	--
GU Genitourinary				
GUBDDMVAC	Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, vinBLAStine, DOXOrubicin and CISplatin	<i>Dose modifications clarified</i>	<i>Pre-treatment metrics corrected</i>	--
HN Head and Neck				
HNOTLEN	Therapy for Locally Recurrent or Metastatic, RAI-refractory Differentiated Thyroid Cancer Using Lenvatinib	<i>Eligibility updated</i>	--	--
LU Lung				
LUAVPEM	Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed	--	<i>Pre-treatment metric clarified</i>	--
LUAVPMTN	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed	--	<i>Pre-treatment metric clarified</i>	--
LK Leukemia				
LKATOATRA	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid)	<i>Tests, Premedications, Treatment, Dose Modifications and Precautions updated</i>	--	--
LKATOP	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and DAUNOrubicin	<i>Tests, Premedications, Treatment, Dose Modifications and Precautions updated</i>	--	--
LKATOR	Induction and Consolidation Therapy of Relapsed Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid)	<i>Tests, Premedications, Treatment, Dose Modifications and Precautions updated</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LY Lymphoma				
LYACAL	BC Cancer Protocol Summary for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib	<i>Eligibility and exclusion updated, cautions added, tests, supportive medications, and precautions updated</i>	--	--
LYFACAL	BC Cancer Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib	<i>Eligibility updated, exclusions and cautions added, tests, supportive medications, and precautions updated</i>	--	--
LYFIBRU	BC Cancer Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using iBRUtinib	<i>Eligibility updated, exclusion added, cautions, tests, supportive medications, and precautions updated</i>	--	--
LYIBRU	BC Cancer Protocol Summary for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using iBRUtinib	<i>Eligibility updated, exclusion added, caution, tests, supportive medications and precautions updated</i>	--	--
LYIDELAR	BC Cancer Protocol Summary for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Using Idelalisib and ritUXimab	<i>(Eligibility, exclusions, tests, supportive medications, and precautions updated</i>	--	--
LYOBCHLOR	BC Cancer Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with oBINutuzumab and Chlorambucil	<i>Tests, premedications, supportive medications, and precautions updated</i>	<i>Premedications Updated</i>	--
LYVENOB	BC Cancer Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and oBINutuzumab	<i>Tests, premedications, supportive medications, and precautions updated</i>	<i>Premedications Updated, prechemo metrics and labs clarified</i>	--
ULYWMZANU	BC Cancer Protocol Summary for Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Zanubrutinib	<i>Protocol code revised, tests, supportive medications and precautions updated</i>	<i>Protocol code revised</i>	<i>Protocol code revised</i>

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol Title	Protocol	PPPO	Handout
MY Myeloma				
MYBLDF	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	--
MYBLDPRE	Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant	<i>Tests updated</i>	<i>Tests updated</i>	--
MYBORMTN	Maintenance Therapy of Multiple Myeloma using Bortezomib for Patients with the High-Risk Chromosome Abnormality	<i>Tests updated</i>	<i>Tests updated</i>	--
MYBORPRE	Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant	<i>Tests updated</i>	<i>Tests updated</i>	--
MYBORREL	Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide	<i>Tests updated</i>	<i>Tests updated</i>	--
MYBSD	Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide	<i>Tests updated</i>	<i>Tests updated</i>	--
MYCARDEX	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide	<i>Tests updated</i>	<i>Tests updated</i>	--
MYCARLD	for Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	--
MYDARBD	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone With or Without Cyclophosphamide	<i>Tests updated</i>	<i>Tests updated</i>	--
MYDARCBDF	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	--
MYDARLD	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone With or Without Cyclophosphamide	<i>Tests updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol Title	Protocol	PPPO	Handout
MYDARLDF	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	--
MYLDREL	Therapy of Relapsed Multiple Myeloma using Lenalidomide with Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	--
UMYISACARD	Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	<i>Tests updated</i>	<i>Tests updated</i>	--
UMYISAPOMD	Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	<i>Tests updated</i>	<i>Tests updated</i>	--
UMYLDF	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Lenalidomide with Low-dose Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	--
MYLENMTN	Maintenance Therapy of Multiple Myeloma using Lenalidomide	<i>Tests updated</i>	<i>Tests updated</i>	--
MYMP	Treatment of Multiple Myeloma using Melphalan and Prednisone	<i>Tests updated</i>	<i>Tests updated</i>	--
MYMPBOR	Treatment of Multiple Myeloma using Melphalan, predniSONE and Weekly Bortezomib With the Option of Substituting Cyclophosphamide for Melphalan	<i>Tests updated</i>	<i>Tests updated</i>	--
UMYPOMDEX	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	--
SA Sarcoma				
SAAVGEMD	Therapy for Soft Tissue Sarcomas using Gemcitabine and DOCETaxel	<i>Tests updated, premedications clarified</i>	--	--

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638	nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@ehcnet.phsa.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247	mclin@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
 Jeevan Dosanjh, RN, BScN
 Alina Gerrie, MD, MPH, FRCPC

Samuel Hackett, RN, BScN, CON(C)
 Alison Pow, BScPharm